SCHEMBL3248749

SCHEMBL3248749

Fc1cccc(NCc2cc[c]c(Cl)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.51
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 5/20 0.48
NOS1 P29475 1/20 0.48
HDAC4 P56524 1/20 0.44
MEF2D Q14814 1/20 0.44
ALDH1A1 P00352 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DEPTOR Q8TB45 1/20 0.41
POLB P06746 2/20 0.41
TP53 P04637 1/20 0.41
LMNA P02545 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240341 0.83 LMNA (0.42) MEN1KMT2AMAPTHDAC4MEF2D
SCHEMBL3247153 0.82 HPGD (0.51) HPGDMEN1KMT2AMAPTNOS1
SCHEMBL3247409 0.81 HPGD (0.45) HPGDMEN1KMT2AMAPTNOS1
SCHEMBL3242481 0.79 MAPT (0.43) MEN1KMT2AMAPTALDH1A1POLB
SCHEMBL6229701 0.79 HPGD (0.65) HPGDMEN1KMT2AMAPTNOS1
SCHEMBL10055035 0.77 HPGD (0.67) HPGDMEN1KMT2AMAPTNOS1
SCHEMBL3246912 0.77 MAPT (0.45) MEN1KMT2AMAPTALDH1A1FFAR1
SCHEMBL3246772 0.76 NPC1 (0.46) HPGDMEN1KMT2AMAPTHDAC4
SCHEMBL6696141 0.76 HPGD (0.60) HPGDMEN1KMT2AMAPTNOS1
SCHEMBL11015099 0.74 HPGD (0.63) HPGDMEN1KMT2AMAPTNOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP claimed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO claimed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP disclosed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO disclosed